News

Viewbix Secures $3 Million in Investment to Expand Operations

Viewbix Secures $3 Million in Investment to Expand Operations

Viewbix Announced Significant Funding for Growth

Viewbix Inc. (NASDAQ: VBIX), a pioneering entity in the ad-tech industry, has recently revealed that it successfully entered into agreements with specific investors to raise approximately $3 million through the sale of common stock and pre-funded warrants. This transaction, priced above the company's prevailing market price, signifies investor confidence in Viewbix's potential.

Details of the Investment Deal

The private placement will involve the issuance of around 800,000 units, each consisting of one common share and one warrant. The common units are priced at $3.75 each, while the pre-funded units offer the same pricing, with minor adjustments based on the warrant exercise cost. This strategic move will enhance the company's capital structure and support its ongoing initiatives.

Strategic Use of Proceeds

With vision in mind, Viewbix plans to channel the funds from this investment towards exploring fresh business opportunities and investments across various innovative sectors. This aligns with the company's ongoing strategy to diversify and solidify its market presence. The anticipated gross proceeds from this strategic investment are approximately $3 million.

Future Directions Following the Funds

Post-transaction, the company intends to employ the net proceeds alongside existing cash reserves for general corporate purposes. These may include working capital requirements, addressing debts, and furthering expansion efforts in the tech-driven advertising space.

Closing Upcoming in 2025

Scheduled to close in December 2025, the completion of this private placement is contingent upon meeting customary stipulations and fulfilling shareholder approvals. Also contributing to the transaction is the company’s pursuit of acquiring Quantum X Labs Ltd., a firm dedicated to quantum computing and AI, which represents a significant step towards modernizing its operational capabilities.

About Viewbix and Its Operations

Viewbix, via its subsidiaries like Gix Media Ltd. and Cortex Media Group Ltd., specializes in the digital advertising domain. The group is characterized by two main functions: search and content generation. The search division focuses on creating software that optimizes user traffic acquisition. Meanwhile, the digital content arm is involved in crafting and tailoring content in multiple languages, designed to attract diverse audiences and maximizing ad revenue from platforms like Google, Facebook, Yahoo, and Apple.

Technological Edge in Advertising

With a deep commitment to enhancing advertising strategies, Viewbix equips clients to achieve higher profitability from their campaigns, utilizing cutting-edge tools specifically designed for internet marketing. This strategic emphasis on technological advancement further establishes its leadership in the industry.

Contact Information

For further insights into operations or investment opportunities, Michal Efraty, Head of Investor Relations, can be reached at michal@efraty.com. Viewbix continues to remain at the forefront of digital advertising innovation, consistently evolving to meet the demands of its clientele.

Frequently Asked Questions

What is the purpose of the recent investment deal announced by Viewbix?

The investment aims to fund new business opportunities and strategic advancements within the digital advertising sector.

How much capital is Viewbix raising in this private placement?

Viewbix is raising approximately $3 million through the issuance of common stock and pre-funded warrants.

What is included in the investment units offered by Viewbix?

Each unit comprises one share of common stock and one common warrant exercisable at a predetermined price.

When is the closing date for this private placement?

The closing is anticipated to occur in December 2025, subject to meeting specified conditions.

What are the long-term goals for Viewbix post-investment?

Viewbix aims to enhance its digital advertising technologies and explore innovative opportunities, bolstering its industry presence.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 20

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 206

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 234

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 183

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 223

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 219

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Sodium Bisulfite Market by 2034

Updated Category News Views 133

Understanding the Growth of the Sodium Bisulfite Market The sodium bisulfite market is experiencing significant momentum as it progresses towards a bright future, with expectations of reaching USD 1,180.7 million by 2034, up from USD 750.3 million in 2024. This growth is driven by an increasing awareness of environmental issues and its versatile applications in various...

Continue Reading
Photocure ASA Reports Impressive Q2 Growth and Outlook

Updated Category News Views 153

Photocure ASA Achieves Record Revenue in Q2 Photocure ASA has shared strong results for the second quarter of the year, showcasing remarkable growth in its Hexvix/Cysview product line. This quarter marked an unprecedented achievement with revenues reaching NOK 135.6 million, reflecting a significant increase compared to NOK 122.4 million from the same period last year....

Continue Reading
Ben & Jerry's Unveils New Flavor Inspired by Noah Kahan

Updated Category News Views 273

Ben & Jerry's Launches Exclusive Flavor with Noah Kahan Ben & Jerry's, the iconic ice cream brand that loves to explore creative flavors, has just introduced an exciting new flavor called Northern Latte-tude. This one-of-a-kind creation is the result of a collaboration with musician Noah Kahan, with the goal of not only delighting fans but also supporting an important...

Continue Reading
Cisco Analyst Coverage Initiation Highlights: Stocks to Watch

Updated Category News Views 141

Latest Analyst Ratings on Notable Stocks In a dynamic market environment, top analysts analyze and provide insights on various companies. Recently, several key analysts have shared significant ratings and price targets for notable stocks, including Cisco Systems, Inc. (NASDAQ: CSCO) and Shopify Inc. (NASDAQ: SHOP). Let's delve into what they have to say. Shopify Inc....

Continue Reading
Nike's Leadership Shakeup: A Bright Future Ahead for the Brand

Updated Category News Views 205

Nike's Steady Outlook Amid Leadership Changes BMO Capital Markets has recently reaffirmed its Outperform rating for Nike Inc. (NYSE:NKE), setting a price target at $92.00 per share. This positive outlook follows the recent appointment of Elliott Hill as President and CEO, a change many investors have eagerly awaited. Hill's return is seen as a hopeful sign for the...

Continue Reading